Arch Biopartners Inc (ARCH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arch Biopartners Inc (ARCH) has a cash flow conversion efficiency ratio of 0.072x as of March 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-465.38K) by net assets (CA$-6.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arch Biopartners Inc - Cash Flow Conversion Efficiency Trend (1997–2023)
This chart illustrates how Arch Biopartners Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arch Biopartners Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arch Biopartners Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SUSTAINABLE POWER CL.A
F:9QE
|
N/A |
|
CLPS INC. DL-0001
F:1UK
|
N/A |
|
B&M European Value Retail SA
LSE:BME
|
0.300x |
|
THEWORKS.CO.UK PLC LS-01
F:6EU
|
N/A |
|
Lleidanetworks Serveis Telematics SA
MC:LLN
|
0.270x |
|
Konsortium Transnasional Bhd
KLSE:4847
|
-0.286x |
|
Isofol Medical AB
ST:ISOFOL
|
-0.100x |
|
Japan Gold Corp
V:JG
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Arch Biopartners Inc (1997–2023)
The table below shows the annual cash flow conversion efficiency of Arch Biopartners Inc from 1997 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-09-30 | CA$-5.51 Million | CA$-234.07K | 0.042x | -82.41% |
| 2022-09-30 | CA$-4.47 Million | CA$-1.08 Million | 0.242x | -68.53% |
| 2021-09-30 | CA$-3.88 Million | CA$-2.98 Million | 0.768x | +55.91% |
| 2020-09-30 | CA$-3.87 Million | CA$-1.90 Million | 0.492x | -20.82% |
| 2019-09-30 | CA$-2.90 Million | CA$-1.80 Million | 0.622x | -79.66% |
| 2018-09-30 | CA$-1.05 Million | CA$-3.20 Million | 3.058x | +126.66% |
| 2017-09-30 | CA$-563.41K | CA$-760.17K | 1.349x | -52.55% |
| 2016-09-30 | CA$-256.91K | CA$-730.53K | 2.843x | +184.73% |
| 2015-09-30 | CA$141.48K | CA$-474.82K | -3.356x | -105.55% |
| 2014-09-30 | CA$-6.58K | CA$-398.51K | 60.517x | +14513.69% |
| 2013-09-30 | CA$-425.37K | CA$-176.15K | 0.414x | -49.91% |
| 2012-09-30 | CA$-355.42K | CA$-293.82K | 0.827x | -51.89% |
| 2011-09-30 | CA$-174.98K | CA$-300.68K | 1.718x | +237.73% |
| 2010-09-30 | CA$164.87K | CA$-205.71K | -1.248x | -207.77% |
| 2009-09-30 | CA$-345.96K | CA$-400.53K | 1.158x | +718.19% |
| 2008-09-30 | CA$-1.77 Million | CA$-251.16K | 0.142x | -5.56% |
| 2007-09-30 | CA$-1.01 Million | CA$-151.81K | 0.150x | +180.51% |
| 2006-09-30 | CA$-644.38K | CA$119.92K | -0.186x | -135.10% |
| 2005-09-30 | CA$-887.26K | CA$-470.38K | 0.530x | -64.76% |
| 2004-09-30 | CA$-639.29K | CA$-961.78K | 1.504x | +139.16% |
| 2003-09-30 | CA$73.10K | CA$-280.87K | -3.842x | +82.41% |
| 2002-09-30 | CA$17.10K | CA$-373.42K | -21.841x | -1484.77% |
| 2001-09-30 | CA$-159.43K | CA$-251.46K | 1.577x | +501.48% |
| 2000-09-30 | CA$2.05 Million | CA$-803.47K | -0.393x | +50.09% |
| 1999-09-30 | CA$1.06 Million | CA$-834.06K | -0.787x | -120.14% |
| 1998-09-30 | CA$-128.74K | CA$-503.20K | 3.909x | -91.29% |
| 1997-09-30 | CA$-22.22K | CA$-997.15K | 44.884x | -- |
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related … Read more